Sucrase-Isomaltase Deficiency, Congenital

PRINCETON, NJ, June 4, 2024 /PRNewswire/ - Medunik USA, member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth Project, is pleased to announce the expansion of its UNIK Support Program specialty pharmacy network to now include both Accredo Health Group and CVS Specialty. UNIK Support offers specialized services to benefit patients including a copay savings program, patient care liaison services, mail order pharmacy and other support services. In addition, Arkansas has recently added Pheburane® to its Medicaid Preferred Drug List. As a result, 48 State Medicaid programs now cover Pheburane®, including 12 State Medicaid programs that have included Pheburane® as a preferred covered agent for the treatment of certain UCD patients. Additionally, ~80% of commercially insured Americans have access to Pheburane® coverage, of which more than 75% is preferred coverage. Continue Reading Medunik USA’s UNIK Support Program for Pheburane® expands to now include 2 specialty pharmacy options (CNW Group/Medunik USA) Pheburane® is an innovative adjunctive therapy consisting of very small coated oral pellets (about the size of sugar crystals) for the chronic management of adult and pediatric patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (AS). Pheburane® is not indicated for the treatment of acute hyperammonemia. The most common side effects associated with sodium phenylbutyrate are menstrual dysfunction, decreased appetite, body odor and bad taste or taste aversion.1 Available in Europe since 2013 and in Canada since 2015, Pheburane® has a proven history in the treatment of UCDs at an international level. Medunik USA launched Pheburane® in the USA in September 2022 and since then has significantly widened access to this important treatment option through strategic alliances and cost-effective pricing policies. The widespread preferred coverage for Pheburane® reflects its value proposition and potential to reduce costs within the healthcare ecosystem by 50-70% relative to other taste-masked/nearly tasteless UCD medications*. "The expanded Pheburane® coverage and affordable pricing underscore our commitment to providing Americans with rare diseases access to effective, fairly priced medicines, thus contributing to improving the lives of those whose needs are too often neglected," said Claude-André Boivin, Director, Strategic Pricing and Business Insights, Duchesnay Pharmaceutical Group. UCDs are rare, chronic, genetic conditions that can be fatal if left untreated, and can impact children from the time of birth. UCDs disrupt the body's urea cycle, and therefore, the body is unable to remove the dangerous buildup of toxic chemicals, particularly ammonia, that are created from the digestion of protein. One in 35,000 people in the United States or about 28 per one million residents suffer from UCDs of different levels of severity.2 Medunik USA makes Pheburane® available through its UNIK Support Program designed to support each unique patient. Visit Pheburane.com for more information. About urea cycle disorders (UCDs) The main purpose of the Urea Cycle is to eliminate toxic ammonia from the blood and make urea, which is then excreted as urine. UCDs are rare genetic disorders that cause errors in this process, allowing high levels of ammonia, the key marker for UCDs, to build up in the bloodstream, potentially to dangerous and fatal levels. Ammonia is extremely toxic, particularly to the central nervous system. UCDs can cause catastrophic illness in newborns within 36 to 48 hours of birth despite the infants appearing normal, so they can be discharged from hospital before signs of UCDs develop. UCDs require lifelong monitoring and treatment.2 About Pheburane® Pheburane® is a taste-masked oral formulation of sodium phenylbutyrate, approved by the Food and Drug Administration as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with UCDs, involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Pheburane® is not indicated for the treatment of acute hyperammonemia.1 Pheburane®, developed by Lucane Pharma, is under exclusive distribution in the U.S. through Medunik USA. For further information, visit Pheburane.com. INDICATION AND IMPORTANT SAFETY INFORMATION What is Pheburane®? Pheburane® is a prescription medicine, used along with a specific diet, for the long-term management of adults and children with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (AS). Episodes of sudden, rapid increase of ammonia in the blood (acute hyperammonemia) may happen in people during treatment with Pheburane®. Pheburane® is not used for the treatment of acute hyperammonemia, which can be life-threatening and requires emergency medical treatment. Before taking Pheburane®, tell your healthcare provider about all of your medical conditions, including if you: have heart problems. have kidney or liver problems. have diabetes ( Pheburane® contains sucrose), or have a history of fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency. are pregnant or plan to become pregnant. It is not known if Pheburane® will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if Pheburane® passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby during treatment with Pheburane®. Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may increase the level of ammonia in your blood or cause serious side effects when taken during treatment with Pheburane®. Especially tell your healthcare provider if you or your child take: corticosteroids valproic acid haloperidol probenecid Know the medicines you take. Keep a list of them to show your or your child's healthcare provider and pharmacist when you get a new medicine. What are the possible side effects of Pheburane®? Pheburane® can cause serious side effects, including: Nervous system problems (neurotoxicity). Call your healthcare provider right away if you get any of the following symptoms during treatment with Pheburane®: sleepiness tiredness lightheadedness vomiting nausea headache confusion Low potassium levels in your blood (hypokalemia). Your healthcare provider will monitor your blood potassium levels during treatment with PHEBURANE and treat if needed. Conditions related to swelling (edema). Pheburane® contains salt (sodium), which can cause swelling from salt and water retention. Your healthcare provider will decide if PHEBURANE is right for you if you have certain medical conditions that can cause swelling, such as heart failure, liver problems or kidney problems. The most common side effects of Pheburane® include: absent or irregular menstrual periods decreased appetite body odor bad taste or avoiding foods that you ate prior to getting sick (taste aversion) Your healthcare provider may do certain blood tests to check you or your child for side effects during treatment with Pheburane®. These are not all the possible side effects of Pheburane®. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088. Please read the Full Prescribing Information and Patient Information at Pheburane.com. About Medunik USA Based in Princeton, New Jersey, Medunik USA is part of the Duchesnay Pharmaceutical Group and works to improve the health and quality of life of Americans living with rare diseases by making orphan drug therapies available in the United States. Through its strategic partnerships, Medunik USA develops and provides Americans suffering from rare disease with access to orphan drugs that are not currently available in the U.S. Medunik USA makes critical medications to treat rare diseases available to American patients who might not otherwise have access to these medications. For more information, visit . About Duchesnay Pharmaceutical Group Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the 8 companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least 2 years, in order to accelerate our growth to become an anchor firm in the Canadian economy. Duchesnay Pharmaceutical Group, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations. For more information, please visit . References SOURCE Medunik USA

PRINCETON, NJ, Jan. 23, 2024 /PRNewswire/ - Medunik USA, member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth Project, is pleased to announce that Pheburane® coverage has reached another important milestone to the benefit of Americans with certain urea cycle disorders (UCDs) and is now on the Medicaid Preferred Drug List in 10 states with the recent addition of Georgia, Indiana, Tennessee, and Missouri along with those already in effect in New Hampshire, New Mexico*, North Dakota, Oklahoma, Texas, and Utah*. Pheburane® is also included on the California Contract Drugs List with no prior authorization required and is covered by commercial insurance plans, which now reaches ~80% of the commercially insured US population. Continue Reading Pheburane® (sodium phenylbutyrate) is now on the Medicaid Preferred Drug List in 10 states (CNW Group/Medunik USA) Pheburane® is the safe, effective and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain UCDs. Pheburane® is an innovative formulation of sodium phenylbutyrate consisting of very small coated oral pellets (about the size of sugar crystals) and is indicated for both adult and pediatric patients. Pheburane® is not indicated for the treatment of acute hyperammonemia. The most common side effects associated with sodium phenylbutyrate are menstrual dysfunction, decreased appetite, body odor and bad taste or taste aversion.1 Available in Europe since 2013 and in Canada since 2015, Pheburane® has demonstrated globally its effectiveness in the treatment of UCDs. Pheburane® is a proven treatment with both short-term and long-term (up to 30 months) clinical data establishing its treatment efficacy at lowering ammonia levels in the blood to within normal range2,3 which is crucial as high ammonia levels in the bloodstream may lead to serious and life-threatening health problems for UCD patients.4 "We are glad to contribute to Medunik USA's efforts to facilitate availability of Pheburane® for Americans with certain urea cycle disorders. The widespread access we have been able to achieve reflects the value proposition of Pheburane® to the healthcare system, and we look forward to continuing to assist Medunik USA in their efforts to generate further cost-savings throughout the healthcare industry," said Bill Finneran, President of Viking Healthcare Solutions. With the continued favorable commercial and Medicaid coverage updates, Pheburane® is reaching more patients all over the USA while being recognized as a first-line therapy by health authorities in key states. In other states Pheburane® has equal, or better, coverage as well as being priced at a significant discount to these options: 1/3 of the cost of RAVICTI® (glycerol phenylbutyrate)** and ½ the price of OLPRUVATM (sodium phenylbutyrate)**. UCDs are rare, chronic, genetic conditions that can be fatal if left untreated, and can impact children from the time of birth. UCDs disrupt the body's urea cycle, and therefore, the body is unable to remove the dangerous buildup of toxic chemicals, particularly ammonia, that are created from the digestion of protein. One in 35,000 people in the United States or about 28 per one million residents suffer from UCDs of different levels of severity.4 Medunik USA offers Pheburane® through its UNIK Support Program – designed to support each unique patient. UNIK Support offers specialized services including a copay savings program, patient care liaison services, mail order pharmacy and other support services. Visit Pheburane.com for more information. *Certain Managed Medicaid plans **Based on published pricing information. All trademarks are the property of their respective owners. About urea cycle disorders (UCDs) The main purpose of the Urea Cycle is to eliminate toxic ammonia from the blood and make urea, which is then excreted as urine. UCDs are rare genetic disorders that cause errors in this process, allowing high levels of ammonia, the key marker for UCDs, to build up in the bloodstream, potentially to dangerous and fatal levels. Ammonia is extremely toxic, particularly to the central nervous system. UCDs can cause catastrophic illness in newborns within 36 to 48 hours of birth despite the infants appearing normal, so they can be discharged from hospital before signs of UCDs develop. UCDs require lifelong monitoring and treatment.4 About Pheburane® Pheburane® is a taste-masked oral formulation of sodium phenylbutyrate, approved by the Food and Drug Administration as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with UCDs, involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Pheburane® is not indicated for the treatment of acute hyperammonemia.1 Pheburane®, developed by Lucane Pharma, is under exclusive distribution in the U.S. through Medunik USA. For further information, visit Pheburane.com. INDICATION AND IMPORTANT SAFETY INFORMATION What is Pheburane®? Pheburane® is a prescription medicine, used along with a specific diet, for the long-term management of adults and children with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (AS). Episodes of sudden, rapid increase of ammonia in the blood (acute hyperammonemia) may happen in people during treatment with Pheburane®. Pheburane® is not used for the treatment of acute hyperammonemia, which can be life-threatening and requires emergency medical treatment. Before taking Pheburane®, tell your healthcare provider about all of your medical conditions, including if you: have heart problems. have kidney or liver problems. have diabetes ( Pheburane® contains sucrose), or have a history of fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency. are pregnant or plan to become pregnant. It is not known if Pheburane® will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if Pheburane® passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby during treatment with Pheburane®. Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may increase the level of ammonia in your blood or cause serious side effects when taken during treatment with Pheburane®. Especially tell your healthcare provider if you or your child take: corticosteroids valproic acid haloperidol probenecid Know the medicines you take. Keep a list of them to show your or your child's healthcare provider and pharmacist when you get a new medicine. What are the possible side effects of Pheburane®? Pheburane® can cause serious side effects, including: Nervous system problems (neurotoxicity). Call your healthcare provider right away if you get any of the following symptoms during treatment with Pheburane®: Low potassium levels in your blood (hypokalemia). Your healthcare provider will monitor your blood potassium levels during treatment with PHEBURANE and treat if needed. Conditions related to swelling (edema). Pheburane® contains salt (sodium), which can cause swelling from salt and water retention. Your healthcare provider will decide if PHEBURANE is right for you if you have certain medical conditions that can cause swelling, such as heart failure, liver problems or kidney problems. The most common side effects of Pheburane® include: Your healthcare provider may do certain blood tests to check you or your child for side effects during treatment with Pheburane®. These are not all the possible side effects of Pheburane®. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088. Please read the Full Prescribing Information and Patient Information at Pheburane.com. About Medunik USA Based in Princeton, New Jersey, Medunik USA is part of Duchesnay Pharmaceutical Group and works to improve the health and quality of life of Americans living with rare diseases by making orphan drug therapies available in the United States. Through its strategic partnerships, Medunik USA develops and provides Americans suffering from rare disease with access to orphan drugs that are not currently available in the U.S. Medunik USA makes critical medications to treat rare diseases available to American patients who might not otherwise have access to these medications. For more information, visit . About Duchesnay Pharmaceutical Group Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The group consists of five pharmaceutical companies to meet the needs of patients in Canada, the United States, and abroad. The companies are Duchesnay and Duchesnay USA, both dedicated to women's health; Médunik Canada and Medunik USA, which provide treatments for rare diseases; and Analog Pharma, an American generic drugs company, specializing in authorized generics and orphan drugs. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the 8 companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least 2 years, in order to accelerate our growth to become an anchor firm in the Canadian economy. The Group, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology as well as for rare diseases. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations. For more information, please visit: About Viking Viking Healthcare Solutions has provided market access and commercialization services to the pharma and biotech industries for over 25 years, supporting traditional and rare/specialty products throughout their lifecycle. Our breadth and depth of access, account knowledge, and payer insights empower us to connect manufacturers and payers to drive access to medications for patients in need. References Pheburane® (sodium phenylbutyrate) oral pellets [Prescribing Information]. Medunik USA, Inc. Kibleur Y, Dobbelaere D, Barth M, Brassier A, Guffon N. Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) survey of patients in France treated with Pheburane® (Sodium Phenylbutyrate) taste-masked granules. Paediatr Drugs. 2014. Kibleur Y, Guffon N. Long-Term Follow-Up on a Cohort Temporary Utilization Authorization (ATU) Survey of Patients Treated with Pheburane (Sodium Phenylbutyrate) Taste-Masked Granules. Paediatr Drugs. 2016 Apr;18(2):139-44. doi: 10.1007/s40272-015-0159-8. PMID: 26747635. Cleveland Clinic, Urea Cycle Disorder, SOURCE Medunik USA

PENSACOLA, Fla., Jan. 19, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective analysis of patients who have received Wharton's Jelly applications to the refractory sacroiliac (SI) joint to mitigate loss of function and pain, improving quality of life. Dr. Albert Lai of Desert Pain Specialists and Centers of Rehabilitation and Pain Medicine in California has presented for publication a novel case study of Wharton's Jelly, a mesenchymal connective tissue, applied to the structural tissue defect of the articular cartilage in patients with refractory SI joint dysfunction. Dr. Albert Lai is Double Board-Certified Physician with specialties in Physical Medicine Rehabilitation and Pain Medicine. The homologous use application validated by Lai sets a precedent for non-surgical allograft application. "This new research marks a great advancement in care for those patients suffering from chronic, treatment-resistant SI joint dysfunction. Through this observational study I am able to further commit to outcomes-based medicine and deliver the best care possible for my patient population. Having a safe and minimally invasive alternative to SI fusion surgery is incredible," shared Lai. SI joint-mediated pain affects roughly 15% of the United States population resulting in 12 million physician visits annually. The current standard of care for the SI joint addresses the symptoms involved, with pain medication, braces, or SI fusion. These costs can range upwards of 30k for a fusion, and the cost of pain management continues to rise as treatment does not address the root cause of the pain. The rising annual number of surgeries is enough to implement intraoperative and perioperative protocols that anticipate and present an alternative to invasive arthroscopic repair of the SI joint. To advance the necessary research and fill the need for non-surgical alternatives, Regenative has been tracking data in its comprehensive repository in which physicians across specialties submit patient data as they track patient outcomes up to 120 days after the patient receives an application of Regenative's products, like its Wharton's Jelly allografts. Last month, Regenative announced how preliminary 90-day data on over 50 patients with SI joint defects demonstrates greater than 35% improvement in NPRS & WOMAC scores, indicating improved functionality post-application. "Our retrospective data repository is designed to promote value-based, outcomes-focused physician practices and has inspired clinically significant case studies and statistically significant peer-reviewed research. Our repository is backed by an IRB, ensuring compliant protocols are followed with respect to what is collected," shared Regenative Labs CEO, Tyler Barrett. Barrett is committed to providing patients with alternative options, and through what may be revealed in these studies, offering proven treatments to better address the root cause of their pain. Barrett and his team hope to enlist physicians to take part in studies regarding uncovered uses. Physicians will have their outcomes highlighted, furthering the understanding of regenerative medicine and uncovering new applications for this groundbreaking field of medicine. "We're doing the research at Regenative, and the results are very promising. We are calling on all physicians across the country to engage with us and advance the field of regenerative medicine," Barrett concluded. Contact Regenative to get your practice involved today About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient's conditions using Wharton's Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with the daily challenges of innovations in healthcare, the company provides non-addictive, non-invasive options for patients. Regenative Labs' expert product research and development team comply with FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative's website: About Dr. Albert Lai: A southern Californian native, Lai completed his medical training at Tufts University, where he subsequently served as a clinical instructor. Lai is board certified in Physical Medicine and Rehabilitation. He also holds board certifications in Pain Medicine and Independent Medical Examiners. Lai has served as the managing partner at the offices of Desert Pain & Rehabilitation Associates based in Rancho Mirage for the past 18 years and as medical director of Centers of Rehabilitation and Pain Medicine in Placentia, California. Learn more at the Centers of Rehabilitation webs website: SOURCE Regenative Labs